tada, correct it if I'm wrong but this is the way I see it.
Resverlogix's clinical ambitions thus far focused on its therapeutic potential (apabetalone) in the treatment of Vascular Disease, Covid-19 & Post Covid-19 conditions.
Zenith is focused on the development of the BETi combination therapies for multiple oncology indications, with its lead BET inhibitor, ZEN-3694 in collaboration with BP in several oncology clinical studies.
Koo